Exelixis' Expanded Adagene Partnership: Navigating the Impact on Oncology Pipeline and Earnings Outlook

Exelixis, a pharmaceutical company, has partnered with Adagene to use their SAFEbody technology to develop next-generation antibody-drug conjugates for solid tumors. This deal could expand Exelixis's pipeline and impact their earnings outlook. The company's reliance on CABOMETYX, which accounts for over 90% of revenue, remains a concern, while the Adagene deal does not directly mitigate this risk. Exelixis anticipates $3.1 billion in revenue and $1.1 billion in earnings by 2028, with a fair value of $44.06 and a 9% upside to its current price.

Exelixis, a leading pharmaceutical company, has entered into an expanded collaboration with Adagene (Nasdaq: ADAG) to leverage the latter's SAFEbody technology for the development of next-generation antibody-drug conjugates (ADCs) targeting solid tumors. The agreement, which amends their 2021 partnership, sees Exelixis utilizing Adagene's proprietary SAFEbody platform to create a masked monoclonal antibody for a solid tumor target from Exelixis' pipeline Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate^[1].

Under the terms of the amended agreement, Exelixis will use Adagene's SAFEbody technology to develop a third masked ADC. The SAFEbody platform is designed to make antibodies invisible until they reach tumor cells, avoiding unwanted binding to healthy cells. This technology addresses a critical challenge in cancer therapeutics—off-target toxicity Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate^[1].

Adagene will receive development and commercialization milestones plus royalties on net sales of products developed under this agreement. The lead SAFEbody candidate, ADG126, is currently in a Phase 1b/2 study for metastatic microsatellite-stable colorectal cancer, with Phase 2 expected to start by the end of 2025 Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate^[1]. This deal structure follows the typical biotech partnering model, where Adagene will receive tiered royalties that could represent significant long-term value if products reach commercialization.

For Exelixis, this collaboration represents a significant commercial validation of Adagene's SAFEbody platform technology. The company's reliance on CABOMETYX, which accounts for over 90% of its revenue, remains a concern. While the Adagene deal does not directly mitigate this risk, it does expand Exelixis's pipeline and could impact its earnings outlook. Exelixis anticipates $3.1 billion in revenue and $1.1 billion in earnings by 2028, with a fair value of $44.06 and a 9% upside to its current price .

Adagene's SAFEbody technology holds promise for safer cancer therapies by minimizing on-target off-tumor toxicity in healthy tissues. The company's lead clinical program, ADG126, is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells in the tumor microenvironment. ADG126 is currently in Phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on MSS CRC Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate^[1].

This expanded partnership demonstrates continuing external validation of Adagene's technology platform while potentially providing additional non-dilutive funding to support their pipeline development. For a biotech company, securing multiple deals with an established partner like Exelixis suggests their platform technology offers meaningful advantages over competing approaches.